PMID: 7518981Jul 1, 1994Paper

Safety assessment of terazosin in the treatment of patients with symptomatic benign prostatic hyperplasia: a combined analysis

Urology
F C Lowe

Abstract

This study reviews and assesses the safety of terazosin for the treatment of symptomatic benign prostatic hyperplasia (BPH). Six placebo-controlled trials (including two unpublished series) involving 996 patients provide the database for this evaluation. Six hundred thirty-six patients received terazosin from 1 to 20 mg daily for a total of 229 patient-years of exposure to terazosin. The most common final dose of terazosin was 10 mg once daily. Side effects were generally mild or moderate in severity and resolved following cessation of therapy. Side effects resulted in premature withdrawal in 9% of terazosin-treated patients and 7% of placebo-treated patients (difference not significant). Dizziness (2.0%) and headache (1.1%) were the most common symptoms leading to premature withdrawal from the studies. Although postural symptoms and dizziness were slightly more common in those terazosin-treated patients 65 or more years old compared with patients less than 65 years old, this difference was not statistically significant. Only 4 of the 636 patients (0.6%) had syncopal episodes; 2 of these occurred at initiation of terazosin therapy or at dose escalation. Minimal reductions in blood pressure were observed in normotensive patients...Continue Reading

References

Aug 1, 1976·British Journal of Urology·M CaineS Perlberg
Oct 1, 1977·The British Journal of Surgery·P F BorehamH Pearson
Oct 1, 1982·British Journal of Urology·P H AbramsR G Choa

❮ Previous
Next ❯

Citations

Jul 3, 2003·Urology·Barbara B M KortmannJean J M C H de la Rosette
Nov 1, 1995·Urology·M P O'LearyM J Barry
Feb 23, 1999·The Urologic Clinics of North America·H L Holtgrewe
Jul 7, 2007·Nature Clinical Practice. Urology·Karl-Erik Andersson, Christian Gratzke
Jun 26, 2001·British Journal of Clinical Pharmacology·M C MichelH Rübben
Aug 19, 2011·The Journal of Pharmacology and Experimental Therapeutics·Marcus M Reidenberg
Mar 11, 2006·Drugs·Marleen M van DijkMartin C Michel
Jan 10, 2001·Current Opinion in Urology·C R Chapple
Nov 1, 1994·Seminars in Nephrology·R A Appell
Feb 3, 2007·Current Medical Research and Opinion·Jed Kaminetsky
Apr 29, 2005·International Journal of Clinical Practice·D J Martin, J P Mulhall
Sep 1, 1995·The Journal of Urology·L M Eri, K J Tveter
Jul 31, 1998·Lancet·N Hernández-CanoM Casado
Nov 5, 2003·Expert Opinion on Pharmacotherapy·David M Weiner, Franklin C Lowe
Aug 23, 2003·International Journal of Impotence Research·D J Carbone, S Hodges
Mar 29, 2002·International Journal of Impotence Research·J S GreenW G Bowsher
Jul 21, 2007·British Journal of Health Psychology·Susan HaleSara Willott
Feb 15, 1997·The Prostate·K E AnderssonM G Wyllie
Apr 1, 1997·The Annals of Pharmacotherapy·M Lee, R Sharifi

❮ Previous
Next ❯

Related Concepts

Related Feeds

ApoE, Lipids & Cholesterol

Serum cholesterol, triglycerides, apolipoprotein B (APOB)-containing lipoproteins (very low-density lipoprotein (VLDL), immediate-density lipoprotein (IDL), and low-density lipoprotein (LDL), lipoprotein A (LPA)) and the total cholesterol/high-density lipoprotein (HDL) cholesterol ratio are all connected in diseases. Here is the latest research.